Correction: IL-17A weakens the antitumor immunity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice

Juan Wang; Yue Zhang; Kai Yin; Peiqi Xu; Jie Tian; Jie Ma; Xinyu Tian; Yungang Wang; Xinyi Tang; Huaxi Xu; Shengjun Wang

doi:10.18632/oncotarget.28052

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: IL-17A weakens the antitumor immunity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice

PDF | How to cite

Oncotarget. 2022; 13:425-425. https://doi.org/10.18632/oncotarget.28052

Metrics: PDF 913 views | ?

Juan Wang^1,2,4,*, Yue Zhang^1,*, Kai Yin^3,*, Peiqi Xu², Jie Tian², Jie Ma², Xinyu Tian², Yungang Wang², Xinyi Tang², Huaxi Xu² and Shengjun Wang^1,2

¹Department of Laboratory Medicine, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China
²Institute of Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
³Department of General Surgery, The Affiliated Hospital, Jiangsu University, Zhenjiang, China
⁴Department of Laboratory Medicine, Changzhou TCM Hospital, Changzhou, China
^*These authors contributed equally to this work

Published: February 18, 2022

Copyright: © 2022 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during figure assembly, an accidental duplicate image of panel 4 in Figure 1F was inserted in panel 2 of Figure 1F. The corrected Figure 1F, obtained using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2017; 8:4814-4825. DOI: https://doi.org/10.18632/oncotarget.13978

Figure 1: IL-17 inhibits apoptosis of MDSCs. MDSCs were isolated from tumor bearing mice and were then treated with different doses of IL-17. (F) Representative apoptosis analysis of MDSCs treated with IL-17 for 24 h by flow cytometry.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28052

Publication Alerts

Corrections:

Correction: IL-17A weakens the antitumor immunity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice